AU Stock MarketDetailed Quotes
TYP Tryptamine Therapeutics Ltd
- 0.034
- -0.004-10.53%
20min DelayMarket Closed Dec 20 16:00 AET
43.40MMarket Cap-0.37P/E (Static)
0.040High0.034Low2.75MVolume0.038Open0.038Pre Close100.03KTurnover0.05752wk High0.34%Turnover Ratio1.28BShares0.01752wk Low-0.038EPS TTM27.39MFloat Cap0.057Historical HighLossP/E (Static)805.64MShs Float0.017Historical Low-0.091EPS LYR15.79%Amplitude--Dividend TTM8.50P/B1Lot Size--Div YieldTTM
About Tryptamine Therapeutics Ltd Company
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Company Profile
SymbolTYP
Company NameTryptamine Therapeutics Ltd
Founded2013
MarketASX
Employees50
Fiscal Year Ends06-30
AddressC/o Bio101 Financial Advisory Pty Ltd 697 Burke Road, Suite 201
CityMelbourne
CountryAustralia
Zip Code3124
Phone+61 390920475
Share RegistryAUTOMIC REGISTRY SERVICES
Level 5, 126 Phillip Street, SYDNEY, NSW, AUSTRALIA, 2000
02 9698 5414
Company Executives
- Name
- Position
- Salary
- Peter Molloy
- Chief Business Officer and Executive Director,Non-Executive Director
- --
- Mark Davies
- Non-Executive Chairman,Non-Executive Director
- --
- Jason Carroll
- Non-Executive Director
- --
- Gage Jull
- Non-Executive Director
- --
- Clarke Barlow
- Non-Executive Director
- --
- Christopher Ntoumenopoulos
- Non-Executive Director
- --
Heat List
AU
Overall
Symbol
Price
% Chg
No Data